Navigation Links
Pharmaceutical M&A in the Asia Pacific Region
Date:1/16/2012

NEW YORK, Jan. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical M&A in the Asia Pacific Region

http://www.reportlinker.com/p0760637/Pharmaceutical-MA-in-the-Asia-Pacific-Region.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Introduction

Slowing growth continues in major developed markets, prompted by generic erosion of branded sales and increasing regulatory and cost containment pressures. Expansion into emerging Asia Pacific (APAC) markets is appealing not only because of their rapid growth and sizeable patient populations, but also because operating environments are improving as these countries open up to global trade.

Features and benefits

* Overview of drivers, resistors and trends within the Asia Pacific M&A landscape.* Summary of geographic M&A activity on a regional and country-specific basis.* Analysis of the types of acquisitions and healthcare sectors targeted.* Examination of transaction values and leading dealmakers.

Highlights

India, Japan and Australia all continued to record frequent deal activity, although China increased its lead in terms of total deal numbers in 2010 and early 2011. However, Chinese companies continue to focus primarily on domestic transactions.Japanese companies still account for the majority of M&A deal value. The first half of 2011 has already surpassed previous peak M&A deal values in APAC, continuing the annual upward trend seen in transaction values when outlying multi-billion dollar deals are excluded.While most M&As involving APAC-based players target pharmaceutical and biological products companies, such as generics and active pharmaceutical ingredient (API) manufacturers, medical devices and equipment firms have recently taken over as the leading sector targeted for M&A.

Your key questions answered

* Which are the most highly valued pharmaceutical sectors for acquirers, and which companies have been the most acquisitive in APAC in recent years?* Which APAC markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma?

Executive SummaryIntroduction

Strategic scoping and focusKey findingsM&A in APAC are driven by slowing growth in major markets and domestic consolidationAcquisitions are often used to gain a foothold in new Asian markets, where better healthcare is driving increased demand for quality Western medicinesChina, India, and Japan continue to dominate M&A activity in the APAC regionKey definitionsCompany classificationsAcquisition typesGeographic classificationsOtherRelated reportsUpcoming related reportsOVERVIEW OF M&A ACTIVITYKey findingsDrivers and resistors of APAC M&AStronger growth forecast in emerging compared to developed marketsChanging socio-demographics create patient demand for better healthcarePolicy and regulation changes are creating a more certain business environment in APAC marketsProduct development costs are rising rapidly in developed markets, particularly for clinical trialsOverview of M&A activity by geographyChina is the most common target location for acquisitionsChinese companies are the most common acquirersIndia is the leading APAC target for top ranking pharma companies, but China is catching upDomestic and intra-APAC deals still dominate in the regionOverview of M&A activity by deal type and size100% acquisitions are the principal deal type involving APAC companiesMinority acquisitions are not common, but are often used to solidify other types of relationshipsAcquisitions of complete business units are the most common form of asset purchaseM&A were performed by existing shareholders in a quarter of deals analyzedM&A value is likely to reach the highest annual levels in 2011The value of 100% acquisitions has been rising year-on-year in APACOverview of M&A activity by healthcare sector and therapy areaTherapeutics-focused companies are the most common APAC M&A targetsMedical technology is the most frequent target sector for M&ALeading pharma players differ slightly in their targeted sectorsAcquirers target highest value and volume therapeutic areasCOUNTRY-SPECIFIC M&A ACTIVITYKey findingsAPAC markets with significant M&A activityChinese companies continued to focus on mainly domestic M&A activityM&A activity in India is inconsistent on an annual basisJapanese companies dominated APAC M&A activity in terms of deal valueAustralian assets attracted significant international investmentAPAC markets with moderate M&A activitySingaporean companies have become more frequent targets for M&AM&A activity in South Korea increased consistently to 2010New Zealand attracted M&A partners from only a limited number of developed marketsMalaysian M&A deals are slowly increasing in frequencyThe largest proportion of M&A deals in Taiwan took place in 2008Other APAC countries were involved in few M&A dealsForeign M&A in Thailand was based on pre-existing relationshipsOnly other APAC-based companies sought deals in the PhilippinesIndonesia's single deal involved the sale of a local Big Pharma subsidiaryVietnam is still emerging as an M&A targetBIBLIOGRAPHYPublications and online articlesCompany press releasesDatamonitor productsAPPENDIXMethodologyKey definitionsCompany classificationsAcquisition typesGeographic classificationsOtherExchange rates

To order this report:Pharmaceutical Industry: Pharmaceutical M&A in the Asia Pacific Region

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for ... Island Park on Sunday, with sunny skies, a light breeze and temperatures in the ... , The 5k Run and Walk and 1-mile walk were held to ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):